These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24716406)

  • 1. Inhibition of catechol-o-methyltransferase (COMT) by myricetin, dihydromyricetin, and myricitrin.
    Zhu X; Jia YH
    Pharmazie; 2014 Mar; 69(3):183-6. PubMed ID: 24716406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strong inhibitory effects of common tea catechins and bioflavonoids on the O-methylation of catechol estrogens catalyzed by human liver cytosolic catechol-O-methyltransferase.
    Nagai M; Conney AH; Zhu BT
    Drug Metab Dispos; 2004 May; 32(5):497-504. PubMed ID: 15100171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. O-Methylation of tea polyphenols catalyzed by human placental cytosolic catechol-O-methyltransferase.
    Zhu BT; Patel UK; Cai MX; Conney AH
    Drug Metab Dispos; 2000 Sep; 28(9):1024-30. PubMed ID: 10950844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introductory remarks: Catechol-O-methyltransferase inhibition--an innovative approach to enhance L-dopa therapy in Parkinson's disease with dual enzyme inhibition.
    Nissinen E
    Int Rev Neurobiol; 2010; 95():1-5. PubMed ID: 21095456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of human catechol-O-methyltransferase (COMT)-mediated O-methylation of catechol estrogens by major polyphenolic components present in coffee.
    Zhu BT; Wang P; Nagai M; Wen Y; Bai HW
    J Steroid Biochem Mol Biol; 2009 Jan; 113(1-2):65-74. PubMed ID: 19095062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phytochemicals inhibit catechol-O-methyltransferase activity in cytosolic fractions from healthy human mammary tissues: implications for catechol estrogen-induced DNA damage.
    van Duursen MB; Sanderson JT; de Jong PC; Kraaij M; van den Berg M
    Toxicol Sci; 2004 Oct; 81(2):316-24. PubMed ID: 15254334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-dopa upregulates the expression and activities of methionine adenosyl transferase and catechol-O-methyltransferase.
    Zhao WQ; Latinwo L; Liu XX; Lee ES; Lamango N; Charlton CG
    Exp Neurol; 2001 Sep; 171(1):127-38. PubMed ID: 11520127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemistry and pharmacology of catechol-O-methyltransferase inhibitors.
    Nissinen E; Männistö PT
    Int Rev Neurobiol; 2010; 95():73-118. PubMed ID: 21095460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catechol-O-methyltransferase inhibition in erythrocytes and liver by BIA 3-202 (1-[3,4-dibydroxy-5-nitrophenyl]-2-phenyl-ethanone).
    Soares-da-Silva P; Vieira-Coelho MA; Parada A
    Pharmacol Toxicol; 2003 Jun; 92(6):272-8. PubMed ID: 12787259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Selected Natural Compounds as Dual Inhibitors of Catechol-O-Methyltransferase and Monoamine Oxidase.
    Engelbrecht I; Petzer JP; Petzer A
    Cent Nerv Syst Agents Med Chem; 2019; 19(2):133-145. PubMed ID: 31258092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of human catechol-O-methyltransferase-mediated dopamine O-methylation by daphnetin and its Phase II metabolites.
    Liang SC; Ge GB; Xia YL; Pei-Pei D; Ping W; Qi XY; Cai-Xia T; Ling Y
    Xenobiotica; 2017 Jun; 47(6):498-504. PubMed ID: 27435571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, reduces the peripheral O-methylation of L-DOPA and enhances its availability to the brain.
    Parada A; Soares-da-Silva P
    Pharmacology; 2003 May; 68(1):29-37. PubMed ID: 12660477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvianolic acid B as a substrate and weak catechol-O-methyltransferase inhibitor in rats.
    Qi Q; Cao L; Li F; Wang H; Liu H; Hao H; Hao K
    Xenobiotica; 2015; 45(9):820-7. PubMed ID: 25869243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular recognition at the active site of catechol-O-methyltransferase (COMT): adenine replacements in bisubstrate inhibitors.
    Ellermann M; Paulini R; Jakob-Roetne R; Lerner C; Borroni E; Roth D; Ehler A; Schweizer WB; Schlatter D; Rudolph MG; Diederich F
    Chemistry; 2011 May; 17(23):6369-81. PubMed ID: 21538606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
    Ferreira JJ; Almeida L; Cunha L; Ticmeanu M; Rosa MM; Januário C; Mitu CE; Coelho M; Correia-Guedes L; Morgadinho A; Nunes T; Wright LC; Falcão A; Sampaio C; Soares-da-Silva P
    Clin Neuropharmacol; 2008; 31(1):2-18. PubMed ID: 18303486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. O-methylation of catechol estrogens by human placental catechol-o-methyltransferase: interindividual differences in sensitivity to heat inactivation and to inhibition by dietary polyphenols.
    Zhu BT; Wu KY; Wang P; Cai MX; Conney AH
    Drug Metab Dispos; 2010 Oct; 38(10):1892-9. PubMed ID: 20606002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catechol-O-methyltransferase in complex with substituted 3'-deoxyribose bisubstrate inhibitors.
    Ellermann M; Lerner C; Burgy G; Ehler A; Bissantz C; Jakob-Roetne R; Paulini R; Allemann O; Tissot H; Grünstein D; Stihle M; Diederich F; Rudolph MG
    Acta Crystallogr D Biol Crystallogr; 2012 Mar; 68(Pt 3):253-60. PubMed ID: 22349227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease.
    Lindén IB; Nissinen E; Etemadzadeh E; Kaakkola S; Männistö P; Pohto P
    J Pharmacol Exp Ther; 1988 Oct; 247(1):289-93. PubMed ID: 3171977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.